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Abstract
Background: Anemia is a frequent complication after cardiac surgery especially following reoperation due to previous
prosthetic valve failure or multiple valve surgery (including combined coronary artery bypass grafting). This trial
explores whether intravenously administered iron isomaltoside 1000 (Monofer®) results in better clinical outcomes in
patients undergoing complex heart valve surgery who are expected to receive transfusion.
Methods/design: In this prospective, single-center, double-blinded, randomized controlled trial, 214 patients undergoing
reoperation or multiple valve surgery are randomly allocated to either the iron isomaltoside 1000 (IVFe) or the control
group from August 2016 to August 2018. The IVFe group receives iron isomaltoside 1000 mg (maximum dose 20 mg/kg)
intravenously 3 days before and after the surgery. The control group receives an equivalent volume of normal saline. The
primary endpoint is transfusion requirement (more than 1 unit of packed erythrocytes) for postoperative care until
discharge and secondary endpoint are major complications, such as delayed ventilator therapy, acute kidney injury, and
mortality. Reticulocyte count, plasma hepcidin, iron profiles (serum iron, serum ferritin, total iron-binding capacity,
transferrin, transferrin saturation), coagulation profiles, urinary analysis, and chemical profiles are measured for three
preoperative baseline-data days and just before surgery, except for hepcidin. After surgery, daily routine basic laboratory
tests are measured just before discharge and reticulocyte count, iron profiles, and hepcidin are repeatedly checked for
three postoperative days.
Discussions: From our study, we can clarify the following points: the first is the perioperative IVFe effect on the demand
for transfusion, and clinical outcomes in reoperation or complex valve surgery and the second is the role of hepcidin in
the effect of IVFe on the hemoglobin level increase.
Trial registration: ClinicalTrials.gov, Identifier: NCT02862665. Registered on August 2016.
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Background
Anemia is a common postoperative disorder in cardiac
surgery patients after cardiopulmonary bypass (CPB) [1, 2].
Allogeneic blood transfusions (ABT) with red blood cells,
which should be avoided whenever possible, is associated
with complications [3] because ABT carries increased risks
for transmission of infectious diseases and has been clearly
demonstrated to be associated with adverse outcomes
related to postoperative acute kidney injury (AKI), neuro-
logical complications, atrial fibrillation (AF), acute lung
injury, and increased mortality [4–6]. So, many strategies
have been developed to minimize the need for ABT, but
transfusion requirements still remain high [3].
In patients with cardiovascular disease, iron deficiency is
common either due to depletion of whole-body iron stores
(absolute iron deficiency) or because of restricted availability
of iron for erythrogenesis (functional iron deficiency). Thus,
iron therapy is commonly used to reinforce the iron reserve
to prevent anemia after bleeding; however, the effect of iron
replacement after cardiovascular surgery is not clear. Iron
plays an essential role in erythropoiesis and hemoglobin
(Hb) synthesis [7]. The route of iron administration and the
type of iron preparation vary widely. The effectiveness of
iron supplement administration per os is often limited by its
gastrointestinal side effects (10–40%) and low absorption
rate (10–15%) [8, 9]. Therefore, some authors have sug-
gested a role for intravenously administered (IV) iron in
correcting anemia after orthopedic and oncological surgery,
and in renal and obstetric patients [10, 11], but this route
still remains controversial in cardiac surgery. In addition, the
iron-regulatory protein, hepcidin, is responsible for control-
ling dietary iron absorption and body iron distribution [12].
Hepcidin acts by binding to the iron transport protein ferro-
portin, blocking iron absorption from the intestine and iron
release from macrophages, leading to reduced iron delivery
to erythroid precursors [13]. This hepcidin’s role under IV
iron replacement also remains unclear in patients undergo-
ing cardiovascular surgery.
Therefore, in this study, we tried to investigate the effect
of the perioperative administration of IV iron isomaltoside
1000 (Monofer®; Pharmacosmos, Holbaek, Denmark) in
patients undergoing re-do or a complicated valve replace-
ment such as coronary bypass grafting (CABG) combined,
or cases of multiple valve replacement and arrhythmia sur-
gery combined. We also tried to assess the role of hepcidin




This prospective, double-blind, placebo-controlled,
randomized, comparative, single-center trial was planned
in Severance Cardiovascular Hospital, Seoul, Korea from
August 2016 to August 2018 in patients undergoing re-do
(re-do, second re-do, etc.) – or complicated valve
replacement (double valve – aortic, mitral, with or
without tricuspid surgery, CABG combined, arrhythmia
surgery combined) cases. The trial protocol and related
documents were approved by the competent authorities
and Institutional Review Board (IRB) of the University
of Yonsei (approval number: 4-2016-0502). The trial was
conducted in accordance with Good Clinical Practice and
the Declaration of Helsinki. Informed consent was
obtained in writing prior to any trial-related activities. This
trial was registered at ClinicalTrials (ClinicalTrials.gov,
Identifier: NCT02862665) in August, 2016.
Patients will be randomly allocated to either the IV
iron isomaltoside 1000 (IVFe) or the control (normal saline)
group in a 1:1 ratio by means of computer-generated
random numbers. IVFe administration is scheduled at 3
days before and after surgery. The patients will be checked
by laboratory testing five times perioperatively at: (1) the
preoperative baseline visit: reticulocyte count, Hb, plasma
hepcidin, iron profiles (serum iron, serum ferritin, total
iron-binding capacity, transferrin, transferrin saturation),
coagulation profiles (PT, PTT), routine urinary analysis,
and chemical profiles (aspartate aminotransferase (AST)/
alanine aminotransaminase (ALT), serum creatinine,
electrolytes, C-reactive protein (CRP), creatine kinase
(CK), estimated glomerular filtration rate (GFR)), (2)
start of therapy (first injection of IVFe 3 days before
surgery): repeat laboratory test except for plasma hepcidin,
(3) postoperative day 3 (just before the second injection of
IVFe): repeat laboratory test except for urinary analysis,
(4) postoperative day 10 or discharge day: repeat labora-
tory test except for plasma hepcidin and urinary analysis,
and (5) postoperative week 4: repeat laboratory test except
for plasma hepcidin and urinary analysis (Table 1).
Cr creatinine, Hb hemoglobin, HCt hematocrit, INR
International Normalized Ratio, OPD outpatient
department, OT, POD postoperative day, PT prothrombin
time, PTT partial thromboplastin time, TIBC total iron-
binding capacity, U/A RBC Urinary analysis red blood cells.
The IVFe group received iron isomaltoside 1000 as a
single-dose infusion of 1000 mg over 30 min with a
maximum single dose of 20 mg/kg. The placebo group
received saline (0.9% Sodium Chloride Injection; JW
Pharmaceutical, Seoul, Korea) as a single-dose infusion
of 100 ml over 30 min.
Participants and eligibility criteria
Basically, all patients aged 19 years of age or older undergo-
ing re-do (re-do, second re-do, etc.) – or a complicated
valve replacement (double valve – aortic, mitral, with or
without tricuspid surgery, CABG combined, arrhythmia
surgery combined cases) are included. Eligibility will be de-
termined by two cardiac surgeons and two cardiac anesthe-
siologists on the basis of the preoperative evaluation results.
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After completing the screening, participants will be guided
through the informed consent process and written in-
formed consent will be obtained from all participants be-
fore the initiation of any preoperative iron treatment. After
consent forms are signed, participants will be randomly al-
located to one of the two groups in a 1:1 ratio (Fig. 1).
Exclusion criteria
Exclusion criteria are as followings: (1) patients who
have critical anemia that cannot be corrected by only
iron replacement therapy (Hb < 9 g/dl for women and
Hb < 10 g/dl for men) such as aplastic anemia, (2)
patients who have end-stage renal disease (ESRD)
treated with erythropoietin or any concomitant medica-
tion for erythropoiesis, (3) patients with previous para-
valvular leakage, because any ensuing hemolytic anemia
cannot be corrected by iron replacement, (4) patients
with a hyperallergic reaction to iron agents, and aplas-
tic anemia, and (5) patients who have been treated in
intensive care unit for severe cardiac dysfunction.






















Before surgery 2–3 days / / / (±)
Just before surgery / / / (±)
POD0 / / / (±)
POD1 / / / (±)
POD2 / / /
POD3 / / /
POD4 / / /
POD5 / / /
POD6 / / /
POD7 / / /
POD10 or discharge day / / /
Follow-up OPD (20) / / /
U/A RBC Urinary analysis red blood cells, GOT Glutamic Oxalacetate Transaminase, GPT Glutamic Pyruvate Transaminase
Fig. 1 Schematic of study design
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Randomization
Patients are randomly allocated to either the IV iron
isomaltoside 1000 (IVFe) or the control (normal saline)
group in a 1:1 ratio by means of computer-generated
random numbers. Random numbers will be generated
by an independent statistics professional using SPSS
version 19.0 for Windows (release 19.0 K; SPSS Inc.
Armonk, NY, USA). Sealed assignment envelopes will
be used for allocation concealment.
Withdrawal and dropout
All participants will have the right to withdraw from the
study at any time. Participation will be terminated if
the individual wants to stop and withdraws consent.
The trial will be stopped if the investigator believes that
there are unacceptable risks to participants. If any patients
show typical complications of IVFe, such as nausea,
vomiting, hypotension, gastric discomfort, urticaria, and
acute renal failure, participation will be terminated imme-
diately. The patients who have Hb concentrations higher
than 8 mg/dl postoperatively, yet require transfusion due
to symptoms of acute anemia, such as shortness of breath,
change in respiratory rate and pulse rate, mental function
deterioration, and myocardial ischemia, are excluded from
the study. Patients with postoperative paravalvular leakage
should be removed to avoid confusion with the possibly
similar effects on red blood cells as hemolytic anemia.
Postoperative gastrointestinal bleeding is excluded. We
also excluded patients who underwent re-exploration for
postoperative bleeding (postoperative bleeding is defined
as total drainage volume < 1000 cm3 during the 4 h after
arrival in the intensive care unit (ICU)).
Intervention
IVFe administration is scheduled twice, at 3 days before
and after surgery, regardless of Hb level. The IVFe group
receives iron isomaltoside 1000 as a single-dose infusion
of 1000 mg over 30 min with a maximum single dose
of 20 mg/kg. The placebo group receives saline (0.9%
Sodium Chloride Injection; JW Pharmaceutical, Seoul,
Korea) as a single-dose infusion of 100 ml over 30 min.
Study objective and outcomes (primary and secondary
outcomes)
The primary objective of the trial is to demonstrate that
IVFe is superior compared to placebo in leading to less de-
crease in the Hb level and reducing the need of transfusion
in patients undergoing complex cardiac surgery, which is a
highly possible scenario for receiving a transfusion. The
secondary objectives are to compare the effects of IVFe on
the clinical (or surgical) outcomes (e.g., renal failure, respira-
tory failure, etc.) from reducing the need for blood transfu-
sion and the stability of iron-related parameters. The final
objective is to assess the role of the iron-regulatory protein,
hepcidin, as a biomarker, as well as any association of
hematological parameters with outcome. Thus, we de-
cided the endpoints as followings: the primary endpoint
is the comparison of perioperative transfusion require-
ments in terms of overall incidence and mean amounts
of units of packed erythrocytes transfused per patient
during and after the operation until discharge, and the
secondary endpoint is the occurrence of postoperative
major advanced complications (delayed ventilator therapy,
AKI and all-cause mortality). A Hb concentration of less
than 7 mg/dl during CPB, and less than 8 mg/dl after CPB
and postoperatively, were used as transfusion thresholds.
Intraoperatively, we measured the Hb concentration post
induction and every 30 min during CPB, then at 10 min
post CPB and post sternal closure, and postoperatively at
the time of, and 8 h after, arrival at the ICU. After the day
of surgery, we measured the Hb concentration in the
morning if there was no excessive bleeding (over 1000 cm3)
or symptoms of anemia. Any patients who have Hb concen-
trations higher than 8 mg/dl postoperatively, yet required
transfusion due to symptoms of acute anemia, such as short-
ness of breath, change in respiratory rate and pulse rate,
mental function deterioration, and myocardial ischemia,
were excluded from the study. We also excluded patients
who had undergone re-exploration for postoperative bleed-
ing (postoperative bleeding was defined by total drainage
volume (< 1000 cm3) during the 4 h after arrival in ICU).
Postoperative variables included the amount of bleeding
measured by chest-tube drainage after surgery, fluid input,
urine output, and overall amount of ABT. Hb concentra-
tions, PT, AST/ALT, and creatinine (Cr) levels were
measured preoperatively, post anesthetic induction, and
postoperative day (POD) 0 (day of the surgery after arrival
in the ICU), 1, 2, 3, 4, and 7. Reticulocyte count and iron
profiles were measured preoperatively and post anesthetic
induction and at POD 3, and POD 10, and the changes in
reticulocyte count from the baseline values were calcu-
lated. Postoperative variables also included the incidence
of perioperative transfusion volume, the incidence of AKI
within 48 h after surgery, new-onset AF after surgery, dur-
ation of ventilator care, ICU stay and hospital stay, and in-
hospital mortality. Multiple ABT is defined as more than
1 unit of packed erythrocytes during the operation and
until discharge. AKI is defined as elevation of serum Cr of
≥ 0.3 mg/dl or 50–200% from baseline using the modified
Risk, Injury, Failure, Loss, and ESRD classification [14].
Surgical mortality is defined as all deaths that occur dur-
ing the hospital stay or after hospital discharge but within
30 days postoperatively.
Data collection
We will collect the clinical data from the laboratory results
of all enrolled patients during admission and at outpatient
clinic follow-up.
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Sample size
Sample size estimation is based on the null and alternative
hypotheses. In our study, the null hypothesis is that “IVFe
has no significantly different effect on Hb level and trans-
fusion need after complex cardiac surgery” and we want
to prove that the null hypothesis is wrong for replacing
the alternative hypothesis by the two-sided test method.
Previous reports [15, 16] suggested a 35% reduction in
transfusion rate using IVFe but we set a higher transfusion
rate (40%) considering the complexity and severity of
cardiac surgery. The sample size calculation was based on
superiority analysis under the hypothesis that all data was
normally distributed data. We set the significance level
at 0.05, the power at 80%, and the effect size was 0.5. A
two-sided test was used and consequentially 97 patients
were need for each group; however, we set each group
as 107 considering a 10% dropout rate (total 214).
Statistical methods
Continuous variables were shown as means ± standard
deviation (SD) and dichotomous variables are shown as
numbers (percentages). Between-group comparisons of
continuous variables were performed using the independent
Student t test. Dichotomous variables were compared using
the chi-square or Fisher’s exact tests, as appropriate. P
values < 0.05 will be considered statistically significant.
Discussion
ABT is a recognized risk factor for morbidity and
mortality after cardiac surgery [6, 17]. Despite efforts to
reduce ABT, it remains common in cardiac surgery.
Several studies have been published about the effect of
erythropoietic agents such as Recombinant Human
Erythropoietin (rHuEPO) [18–20] and IV iron isomalto-
side 1000 (Monofer®) [21, 22]. For rHuEPO, the theoret-
ical basis for selecting the timing of rHuEPO
administration was based on the assumption that a pre-
emptive single dose of rHuEPO may mitigate the inflam-
matory response-induced blunting of erythropoiesis;
however, this hypothesis remains speculative unless we
also evaluate the representative inflammatory markers.
Also, the potential risk of rHuEPO has always been con-
sidered a considerable burden including the possible
complications of rHuEPO which include hypertension,
headache, tachycardia, nausea, vomiting, hypercalce-
mia, diarrhea, and thromboembolic complications. Re-
cently, therefore, direct IV iron replacement agents
have received attention as alternatives to rHuEPO ther-
apy for reducing transfusion need. In various surgical
fields, the effect of IV iron replacement therapy on
clinical outcomes by reducing ABT have been analyzed
and they showed favorable results compared with sim-
ple iron-replacement therapy per os. In the study by
Muñoz et al., ABT, postoperative nosocomial infection,
30-day mortality, and length of hospital stay (LHS)
from 2547 patients undergoing elective lower-limb
arthroplasty (n = 1186) or hip fracture repair (n = 1361)
were compared between patients who received either
very-short-term perioperative IV iron (200–600 mg;
n = 1538), with or without rHuEPO (40,000 IU), or
standard treatment (n = 1009). They suggested that
very-short-term perioperative administration of IV iron,
with or without rHuEPO, in major lower-limb ortho-
pedic procedures are associated with reduced ABT
rates and LHS, without increasing postoperative
morbidity or mortality [16].
Froessler et al. also analyzed whether perioperative IV
iron reduced the need for ABT in abdominal surgery
patients. Seventy-two patients with iron-deficiency anemia
were assigned to the study which suggested that the
administration of perioperative IV iron reduces the need
for ABT, and is associated with a shorter LHS, enhanced
restoration of iron stores, and a higher mean Hb concen-
tration 4 weeks after surgery [15].
Focusing on the cardiac surgery itself, Johansson et al.
explored whether IV iron isomaltoside 1000 (Monofer®)
results in a better regeneration of Hb levels and prevented
anemia compared to placebo in preoperative non-anemic
patients undergoing cardiac surgery. They showed that a
single, perioperative 1000-mg dose of IV iron isomaltoside
1000 significantly increased the Hb level and prevented
anemia 4 weeks after surgery, with a short-term safety
profile similar to placebo [21]. However, this trial was an
exploratory trial with only a small sample size of 60
patients and relatively simple cardiac surgery such as
CABG. So, the actual risk of bleeding is too low to perform
transfusion compared with our protocol. Our protocol
includes patients undergoing complicated valve surgery,
such as re-operation from previous valve failure, combined
with CABG, arrhythmia surgery, etc.; therefore, it is more
easily reproducible to compare ABT rate between groups
in the “real” surgical world. Also, our protocol contains
an analysis of hepcidin effect in which it is unclear how
hepcidin affects the IVFe as it works to increase the Hb
and improve clinical outcomes.
Study status
This study is an ongoing trial and patient recruitment
remains incomplete at the time of submission
(Additional file 1).
Additional file
Additional file 1: SPIRIT checklist. (DOCX 60 kb)
Abbreviations
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